-+ 0.00%
-+ 0.00%
-+ 0.00%

RBC Capital Maintains Outperform on Xenon Pharmaceuticals, Lowers Price Target to $70

Benzinga·09/18/2026 13:55:04
Listen to the news
RBC Capital analyst Brian Abrahams maintains Xenon Pharmaceuticals (NASDAQ:XENE) with a Outperform and lowers the price target from $81 to $70.